Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.

Original title: “Roche cuts muscle-sparing obesity drug after mid-stage disappointment”

The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.

Original title: “Summit snags $2B investment from AstraZeneca, clearing financial overhang”

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

Original title: “AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push”

Investors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s early pipeline.

Original title: “Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal”

To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.

Original title: “3 steps for taking on Novartis in radiopharma: Curium up first”

Partnership brings key medicines to eight markets

Original title: “Grünenthal expands pain portfolio across Asia-Pacific”

The next biopharma advantage will come from the talent and systems that turn discovery into scale.

Original title: “Breakthrough therapies still need builders”

Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and Sanofi and Regeneron’s Dupixent.

Original title: “6 immunology targets to sustain a mammoth I&I market”

Manufacturers are redesigning their processes to balance both better future emergency vaccine mobilization and the more demanding work of maintaining flexible, commercially viable manufacturing networks.

Original title: “After COVID, biomanufacturing tackles preparedness and commercialization challenges”